EOLS Evolus, Inc.
$7.47+1.36%
Last close: · regular session · Last 60 sessions
After-hours $7.51 +0.54% ·
EOLS dilution and offerings
S-3 shelf filed Jun 2026: it registers shares the company can sell later.
- Float
- 52.6M
- Shelf
- S-3
- Last filing
- 8-K · Nov 4, 2026
Latest SEC filings for EOLS
| 8-K | Current report | |
| 10-Q | Quarterly report | |
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 8-K | Current report | |
| EFFECT | ||
| 8-K | Current report | |
| S-3 | Shelf — dilutive | |
| S-3 | Shelf — dilutive |
Dilution today: new offering filings and reverse splits
Active shelf registration (S-3, Jun 2026). Float: 52.6M shares. Latest SEC filing: 8-K on Nov 4, 2026. EOLS closed at $7.47 (+1.36%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for EOLS in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 372
- Website: https://www.evolus.com
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Latest EOLS news
- Evolus outlines $450M-$500M 2028 revenue target while reaffirming 2026 revenue of $330M-$337M Read article
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS Read article
- Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program Read article
- EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.